Clinical Trial

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

Study acronym: OPTICOV
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-10-18; most recent amendment 2026-02-19.
Status change: Not Yet Recruiting → Recruiting 2023-07-27
Trial Details
NCT Number NCT05587894
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions COVID-19, Immunodeficiency
Enrollment 256 participants
Start Date 2023-04-27
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-23